^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Avastin (bevacizumab)

    i
    Other names: R 435, RG435, R435, rhuMAb-VEGF, RO-4876646, RG 435, RO4876646, R-435, RG-435, RO 4876646
    Company:
    Roche
    Drug class:
    VEGF-A inhibitor
    Related drugs:
    15h
    DESTINY PanTumor03: A Study of T-DXd as Monotherapy or in Combination With Anti-cancer Agents in Patients With Selected HER2-expressing Tumors (clinicaltrials.gov)
    P2, N=127, Active, not recruiting, AstraZeneca | Recruiting --> Active, not recruiting
    Enrollment closed • Pan tumor
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 expression
    |
    Avastin (bevacizumab) • Enhertu (fam-trastuzumab deruxtecan-nxki)
    22h
    EGRET: First in Human Study of AZD9592 in Solid Tumors (clinicaltrials.gov)
    P1, N=403, Recruiting, AstraZeneca | Trial completion date: Oct 2027 --> Aug 2028 | Trial primary completion date: Oct 2027 --> Aug 2028
    Trial completion date • Trial primary completion date • First-in-human
    |
    EGFR wild-type
    |
    Avastin (bevacizumab) • Tagrisso (osimertinib) • 5-fluorouracil • leucovorin calcium • tilatamig samrotecan (AZD9592)
    1d
    CHIMERA: Upfront Trastuzumab-Deruxtecan Plus Capecitabine and Bevacizumab for Patients With HER-2 Positive Metastatic Colorectal Cancer. (clinicaltrials.gov)
    P2, N=42, Recruiting, Gruppo Oncologico del Nord-Ovest
    Trial initiation date
    |
    HER-2 (Human epidermal growth factor receptor 2) • CA 19-9 (Cancer antigen 19-9)
    |
    HER-2 overexpression • HER-2 amplification
    |
    Avastin (bevacizumab) • Enhertu (fam-trastuzumab deruxtecan-nxki) • capecitabine
    1d
    STREAM-2: Second-line Treatment With REgorafenib in Advanced RAS-Mutant Colorectal Cancer (clinicaltrials.gov)
    P2, N=60, Recruiting, National Cancer Institute, Naples
    Trial initiation date
    |
    MSI (Microsatellite instability) • UGT1A1 (UDP glucuronosyltransferase family 1 member A1) • DPYD (Dihydropyrimidine Dehydrogenase)
    |
    RAS mutation
    |
    Avastin (bevacizumab) • capecitabine • Stivarga (regorafenib) • oxaliplatin • irinotecan
    1d
    BLITZ: In Situ Injection of Anti-angiogenics in Patients With Brain Arteriovenous Malformations Not Eligible for Exclusion Treatment (clinicaltrials.gov)
    P1, N=20, Not yet recruiting, Assistance Publique - Hôpitaux de Paris
    Trial initiation date
    |
    Avastin (bevacizumab)
    1d
    BRADI: Corticodependent or Corticoresistant Brain Radionecrosis After Radiotherapy for Brain Metastases (clinicaltrials.gov)
    P3, N=84, Recruiting, Institut Cancerologie de l'Ouest | Not yet recruiting --> Recruiting | Trial completion date: Dec 2029 --> Aug 2030 | Trial primary completion date: Mar 2028 --> Aug 2028
    Enrollment open • Trial completion date • Trial primary completion date
    |
    Avastin (bevacizumab)
    3d
    SGT-53 in Children With Recurrent or Progressive CNS Malignancies (clinicaltrials.gov)
    P1, N=0, Withdrawn, SynerGene Therapeutics, Inc. | Not yet recruiting --> Withdrawn
    Trial withdrawal
    |
    Avastin (bevacizumab) • temozolomide • irinotecan • Onivyde (nanoliposomal irinotecan) • SGT-53
    4d
    RESOLUTE Trial Aims to Investigate the Value of Adding Local Ablative Treatment to Standard Systemic Treatment for Unresectable Oligometastatic Colorectal Cancer (clinicaltrials.gov)
    P=N/A, N=6, Active, not recruiting, Australasian Gastro-Intestinal Trials Group | Recruiting --> Active, not recruiting | Phase classification: P2 --> PN/A | N=75 --> 6 | Trial completion date: Jun 2025 --> Dec 2027 | Trial primary completion date: Jun 2024 --> Dec 2025
    Enrollment closed • Phase classification • Enrollment change • Trial completion date • Trial primary completion date
    |
    Avastin (bevacizumab) • Erbitux (cetuximab) • 5-fluorouracil • oxaliplatin • irinotecan
    4d
    The Efficacy and Safety of Systemic Treatment for Managing Recurrent Respiratory Papillomatosis: A Systematic Review and Meta-analysis. (PubMed, J Voice)
    Systemic bevacizumab remains the most mature systemic option with consistent real-world evidence and published dosing guidance. HPV-specific immunotherapy has recently transformed adult RRP management with an FDA-approved, short-course treatment option; ongoing studies will clarify optimal sequencing with bevacizumab and the role of checkpoint inhibition.
    Retrospective data • Journal
    |
    PD-L1 (Programmed death ligand 1)
    |
    Avastin (bevacizumab)
    4d
    MORPHEUS-Lung: biomarkers and clinical response to atezolizumab + bevacizumab + stereotactic body radiotherapy in patients with metastatic non-small cell lung cancer. (PubMed, Lung Cancer)
    These results suggest that activation of T cells and macrophages are associated with a favorable clinical response to atezolizumab + bevacizumab + SBRT. Moreover, CD8 TRM, CD8 exhausted T cells, and CXCL10+ macrophages may serve as potential biomarkers of response to atezolizumab + bevacizumab + SBRT treatment and potentially aid in tailored, precision medicine for individual patients.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • CXCL10 (Chemokine (C-X-C motif) ligand 10) • FABP4 (Fatty Acid Binding Protein 4)
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • docetaxel
    4d
    A Study of Precemtabart Tocentecan With or Without Bevacizumab Compared to Trifluridine/Tipiracil Plus Bevacizumab in Participants With Previously Treated Metastatic Colorectal Cancer (PROCEADE-CRC-03) (clinicaltrials.gov)
    P3, N=1020, Recruiting, EMD Serono Research & Development Institute, Inc. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Avastin (bevacizumab) • Lonsurf (trifluridine/tipiracil) • precemtabart tocentecan (M9140)
    4d
    SN38 PLGA nanoparticles provide sustained antitumor efficacy and ameliorate colitis severity in a murine colitis-associated cancer model. (PubMed, Int J Pharm X)
    Irinotecan is a cornerstone therapy for metastatic colorectal cancer (CRC); however, the poor solubility and instability of its active metabolite, SN38, limit its therapeutic efficacy...In the azoxymethane/dextran sodium sulfate-induced colitis-associated CRC model, intraperitoneal administration of either free SN38 or SN38-PLGA five times per week, combined with bevacizumab, significantly reduced tumor numbers compared with saline controls (7.2 vs. 7.7 vs. 14.8, p < 0.001), with comparable efficacy between the two treatment groups (p = 0.987)...In conclusion, PLGA encapsulation preserves antitumor efficacy while reducing the severity of colitis. SN38-PLGA represents a promising therapeutic platform for colorectal cancer, with the potential to reduce dosing frequency and gastrointestinal toxicity.
    Preclinical • Journal
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • IL1B (Interleukin 1, beta)
    |
    Avastin (bevacizumab) • irinotecan